New Street Research - Novo Nordisk (novob) Novo - $10bn Wegovy in 2024 (BUY, TP DKK800 [750], 13 pgs)

Report

New Street Research

Dominic Rose ...

Naresh Chouhan

EUR 4478.50 For Business Accounts Only

Novo - $10bn Wegovy in 2024 (BUY, TP DKK800 [750], 13 pgs)

Using a similar scrip based analysis that led us to be considerably above consensus at the beginning of 2023, we show consensus is $3bn too low on ‘24 US Wegovy sales. This would drive an ~11% consensus EBIT upgrade next year. We show Novo’s supply chain can comfortably deliver 50k new patient starts per week through Q2-Q424, generating $9.6bn in US Wegovy sales, driving our $10bn Global Wegovy sales forecast for 2024. We now forecast 31% sales & 38% EPS growth in 2024 despite assuming $1bn higher R&D & $1.6bn higher S&D. We increase our PT to DKK800 which reflects our higher near-term forecasts & conservative estimates.
For access to the full note, please contact Naresh Chouhan ( )

03/11/2023 1 EN

Underlying

Novo Nordisk

See profile

Provider

New Street Research

Provided by our team of experienced analysts, our work is idea driven, based on independence of thought, sector expertise, and firmly focussed on fundamentals and valuation.

New Street Research is an independent, partner-owned, research firm specialising in equity and debt research. Our equity research embraces the following sectors:

Pan European Telecom Services and Cable
US Telecoms, Cable, Satellite and Towers
Global Emerging Market Telecoms
Japan Telecoms
Asian Internet
Pan European Healthcare
Global healthcare thematic research

We provide debt research on:

Pan European Telecom Services and Cable

See profile

Analysts

Dominic Rose

Naresh Chouhan

Other Reports on these Companies

New Street Research

Novo - Collapsing Wegovy Prices is Bullish (BUY, TP DKK 1150, 16 pgs)

In this deep-dive, we show that despite our 2027 Wegovy price of just $200/mth in the US, we are ~20% above consensus on Wegovy & ~30% above cons. on Novo’s Obesity portfolio in 2030. We show why we expect pricing to collapse but that market fears on pricing are far too pessimistic. We believe Wegovy will become the US market leader by volume and benefit from step edits from 2027 onwards. We model Commercial & Medicare channels separately for both price & volume & also show compelling evidence that Novo & LLY will shut out new entrants in the late 2020’s. Our own cost/benefit analysis shows We...

EUR 4478.50

September 10, 2024 September 10, 2024 1 EN

New Street Research

Novo - Sema Likely to Work in Alzheimer’s (BUY, TP DKK1150 [1100], 11 pgs)

New analysis of 6 studies shows strong & conclusive evidence that GLP-1 use reduces Alzheimer’s (AD) symptoms, in our view. Novo are trialling oral sema (14mg) in AD, which is due to read out in Sept ’25. Following our analysis, we now assume a 70% chance of success for this trial, which is obviously very high for an AD P3 trial. We show that peak sales could be $10bn even though we assume $150/mth in the US. Furthermore, due to complex manufacturing, those sales could be much more durable. If we are correct, this materially impacts Biogen & LLY. AD analysis increases PT to DKK1150. For access...

EUR 4478.50

July 31, 2024 July 31, 2024 1 EN

New Street Research

Obesity Market Deep-Dive - Part 1: Fragmentation Underestimated

In the 1st of a 3-part series, we show that the obesity market is set to become incredibly complex, with the current duopoly to be weakened, creating several investment opportunities over the coming years. We expect >15 drugs to launch by 2027, with >5 oral & >10 injectable, with >5 different mechanisms, from ~5 different companies. This fragmentation will create much more dynamism than currently assumed by the market. The statin market provides significant learnings for this fragmentation. We show that orals will likely become market leaders, indication expansions will be key & the IRA enforc...

EUR 4478.50

July 15, 2024 July 15, 2024 1 EN

NSR Policy: It’s the Election, Stupid (or Is It?): Comparing Harris and Trump on Leadership

This fifth note evaluates the nature of leadership, particularly at the FCC, the FTC and the DOJ, and how that plays into the likely policy outcomes.

EUR 8957.00

September 27, 2024 September 27, 2024 1 EN

Jonathan Chaplin

Jonathan Chaplin

Altice Pre-3Q24 Model Update

This report covers changes to our model to incorporate recent management commentary at investor conferences. We have increased broadband losses estimate. We also lowered revenue and EBITDA slightly. The company needs to stabilize EBITDA and reduce leverage. Progress on the first remains sluggish and the second won’t be easy. We remain on the sidelines.

EUR 8957.00

September 27, 2024 September 27, 2024 1 EN

Jonathan Chaplin

Jonathan Chaplin

T-Mobile selling 3.45GHz portfolio

We just learned that T-Mobile is selling the remainder of its 3.45GHz portfolio to Columbia Capital. The transaction was filed with the FCC 10 days ago; we just picked up on it. This follows a swap in which T-Mobile got 2.5GHz licenses in exchange for some of its 3.45GHz licenses back in May. T-Mobile is now out of 3.45GHz entirely. Our quick thoughts in this very brief note.

EUR 8957.00

September 27, 2024 September 27, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Novo - $10bn Wegovy in 2024 (BUY, TP DKK800 [750], 13 pgs)

Novo - Collapsing Wegovy Prices is Bullish (BUY, TP DKK 1150, 16 pgs)

Novo - Sema Likely to Work in Alzheimer’s (BUY, TP DKK1150 [1100], 11 pgs)

Obesity Market Deep-Dive - Part 1: Fragmentation Underestimated

NSR Policy: It’s the Election, Stupid (or Is It?): Comparing Harris and Trump on Leadership

Altice Pre-3Q24 Model Update

T-Mobile selling 3.45GHz portfolio

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe